Pharmaceuticals

#Healthcare #Pharmaceuticals

Novartis awarded an Innovation Passport for glomerulopathy treatment

Novartis Pharmaceuticals UK’s investigational oral therapy, iptacopan (LNP023), has been awarded an Innovation Passport for the treatment of C3 glomerulopathy (C3G) by the Medicines and Healthcare products Regulatory Agency (MHRA), National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC).1 The Innovation Passport is… Read More

#News

#Biopharmaceuticals #Pharmaceuticals

COP26: Biopharmaceutical industry actions to tackle climate change 

Ahead of COP26, which began on October 31 in Glasgow and runs until November 12, the Association of the British Pharmaceutical Industry (ABPI) led a joint statement from the pharmaceutical industry alongside other global associations.   Organisations included in the statement were: The European Federation of Pharmaceutical Industries… Read More

#News

#Cancer research #Pharmaceuticals #Public health

UK: Research and clinical trials should be at the heart of NHS recovery 

NHS England and public sector bodies must restart clinical trials as part of the process to improve cancer services the pharmaceutical industry has warned.   David Watson, Executive Director for Patient Access at the Association of the British Pharmaceutical Industry, gave evidence to the Health and Social Care Committee for its inquiry… Read More

#News

#Biotechnology #Clinical trials #Covid-19 #Drug discovery #Pharmaceuticals #Pharmacology

Apeiron Biologics begins Covid-19 trial for inhaled drug candidate

Apeiron Biologics has begun a Phase I trial for inhalation of APN01, a recombinant human angiotensin-converting enzyme 2 developed to treat Covid-19 patients by neutralising SARS-CoV-2 in the lungs and mitigating lung damage caused by the infection.   The double-blind, placebo-controlled, dose-escalation study plans to enroll about 40 healthy volunteers in Austria… Read More

#News

#Neuroscience #Pharmaceuticals

Biotech to develop treatment for neurodegenerative disease 

A team of medical and pharmaceutical experts has founded SynaptixBio, an Oxford-based research company working to develop the world’s first disease-modifying treatment for TUBB4a leukodystrophy, including H-ABC – a debilitating and potentially life-limiting condition. This is a sponsored research agreement with Children’s Hospital of Philadelphia (CHOP) in the US. Read More

#News

#Digital therapeutics #GlobalData #Pharmaceuticals #Therapeutics

Opportunities in Japan’s neurology digital therapeutics market

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions; GlobalData says several opportunities exist in the digital therapeutics market for neurological diseases in Japan.  Shionogi & Co, a partner of Akili Interactive, a prescription digital medicine company of PureTech Health, has… Read More

#News #Trends & Analysis

#Data science #Funding #Pharmaceuticals

€1.3 million seed round to shift pharmaceutical dealmaking online

Pipelinepharma, a European B2B pharmaceutical marketplace, closed a venture seed round led by Practica Capital. The marketplace has facilitated pharmaceutical product licensing, supply, acquisition deals of more than €200 million in value, covering more than 30 markets on five continents. The investment will help attract talent to… Read More

#News

#AI #Covid-19 #Drug discovery #Pharmaceuticals

Understanding impact of pandemic-driven AI on drug discovery

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development. Jeff Elton, CEO of ConcertAI, who has extensive experience in this sector, shares his insight with DDW. There has been a… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Drug development #Pharmaceuticals #R&D

Pharmaceutical industry warned not to undo pandemic advances 

Dr Steve Arlington, President of The Pistoia Alliance, has called on the pharmaceutical industry to continue building on the advances in collaboration it has built over the past two years. Digital transformation has accelerated rapidly during the pandemic, which in turn has greatly improved remote patient monitoring, rapid online… Read More

#News

#Molecular Biology #Neuroscience #Pharmaceuticals

Novel analgesic drug is based on Nobel prize-winning discoveries 

AlzeCure Pharma says its novel clinical candidate drug ACD440 for peripheral neuropathic pain is based on the seminal discoveries of TRPV1 by Professor David Julius, for which he was awarded the Nobel Prize in Medicine 2021.  Julius, Professor and Chair of the Department of Physiology and Morris Herzstein Chair in Molecular Biology… Read More

#News

#Cancer immunotherapy #Lead optimisation #Pharmaceuticals #Radiology

Collaboration offers therapeutic developments in nuclear medicine 

Oncodesign, Covalab, CheMatech and ABX-CRO have partnered to launch the DRIVE-MRT (Molecular RadioTherapy) solution. Designed to offer therapeutic development in nuclear medicine, this encompasses theranostics, from therapeutic target validation, radiolabeled biological vector generation, lead optimisation, preclinical candidate drug generation and IND, to the design and management of clinical trials.  DRIVE-MRT is based on… Read More

#News

#Pharmaceuticals #Whitepaper

Whitepaper examines balances for analytical purposes 

European Pharmacopoeia (Ph. Eur.) General Chapter 2.1.7 Balances for Analytical Purposes was published in July 2021. Compliance with this chapter by January 1, 2022 is mandatory for any pharmaceutical company who manufactures in, or exports into, the European market.   Balances for Analytical Purposes aims to ensure quality control of… Read More

#News

#Business #Pharmaceuticals

South Korea’s drug pricing could boost pharma innovation, says data 

South Korea is supporting innovative pharmaceutical companies by revising the health insurance benefits system. The new system of preferential drug pricing, if designed effectively, can boost innovation in the country’s pharmaceutical research, says GlobalData.  According to GlobalData, the pharmaceutical market in South Korea is estimated to grow at a compound annual growth… Read More

#Business & Investment #News #Trending News #Trends & Analysis

#Drug development #Neurodegenerative disorders #Neuroscience #Parkinson's #Pharmaceuticals

Partnership for commercialisation of Parkinson’s drug in Europe 

BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom.  Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More

#News

#Pharmaceuticals #Schizophrenia #Therapeutics

New potential therapy for schizophrenia patients

Newron Pharmaceuticals has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Results from the study are expected by the fourth quarter of 2022.  Study 008A, a four-week, randomised, double-blind placebo-controlled international study, is designed to evaluate the efficacy, tolerability, and safety (including effects on the… Read More

#News

#Pharma #Pharmaceuticals #Therapeutics

Digital brain biomarker start-up appoints Acacia founder to board 

Monument Therapeutics, a stratified medicine company, today announced Monument Therapeutics the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director. Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.  The… Read More

#Business & Investment #News #Start-up Zone